Abstract
Objective To investigate the characteristics and influence of type 2 diabetes in hepatocirrhosis ascites complicated with spontaneous bacterial peritonitis(SBP) to support clinical management of this condition.
Methods A retrospective study was conducted to collect patients with hepatocirrhosis ascites with hospitalization from January 1, 2016 to June 30, 2019. The patients were classified according to whether they had type 2 diabetes and SBP. Univariate and multivariate binary logistic regression analysis were performed on the data of the two groups.
Results A total of 214 patients were enrolled in the study, including 121 males and 93 females; 21 diabetics and 193 non diabetics; 119 SBP patients and 95 control subjects. There were 18 cases of SBP in hepatocirrhosis ascites complicated with diabetes, accounting for 85.7%, which was significantly higher than that in the non-diabetic group. The times of ascites, age and hospitalization days of cirrhotic ascites complicated with diabetes were 2 (1-3) times, 74 (60-76) years old and 25 (15-36) days, respectively, which were significantly higher than those in the non-diabetic group, P < 0.05. Multivariate analysis showed that diabetes, the times of hepatocirrhosis ascites, hospitalization days and total bilirubin (TBIL) increased the independent risk factors of SBP in hepatocirrhosis ascites, with OR values of 5.126 (1.358-19.345), 1.949 (1.428-2.660), 1.028 (1.010-1.047), 1.006 (1.001-1.010), respectively (P < 0.05).
Conclusion the patients with hepatocirrhosis ascites complicated with diabetes showed older age, longer hospitalization time, more SBP and more ascites; diabetes mellitus, times of ascites, hospitalization days and TBIL increased the risk of SBP in hepatocirrhosis ascites.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research received no external funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All the data received Institutional Review Board (IRB) approval by the Ethics Committee of the Shanghai Public Health Clinical Center.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Corresponding author email in the full text was updated
Data Availability
The study was supported by the Shanghai Public Health Clinical Center for data access.
